Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4UC
|
|||
| Former ID |
DNCL003557
|
|||
| Drug Name |
GS-6615
|
|||
| Synonyms |
Eleclazine; 1443211-72-0; GS-6615; UNII-PUY08529FK; PUY08529FK; 4-(pyrimidin-2-ylmethyl)-7-(4-(trifluoromethoxy)phenyl)-3,4-dihydrobenzo[f][1,4]oxazepin-5(2H)-one; Eleclazine [INN]; Eleclazine [USAN:INN]; Eleclazine (USAN/INN); Eleclazine(GS-6615); GTPL8413; CHEMBL3707392; SCHEMBL14480722; MolPort-044-723-855; YNUAEEJQYHYLMS-UHFFFAOYSA-N; GS6615; ZINC206191652; AKOS030627706; DB12394; SB19622; KS-000006B4; 1,4-Benzoxazepin-5(2H)-one, 3,4-dihydro-4-(2-pyrimidinylmethyl)-7-(4-(trifluoromethoxy)phenyl)-; AS-35245; J3.563.176C
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ischemic heart disease [ICD-11: BA40-BA6Z; ICD-10: I20-I25; ICD-9: 410-414] | Phase 3 | [1], [2] | |
| Long QT syndrome [ICD-11: BC65.0; ICD-10: I49, I49.8] | Phase 3 | [3] | ||
| Company |
GILEAD
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C21H16F3N3O3
|
|||
| Canonical SMILES |
C1COC2=C(C=C(C=C2)C3=CC=C(C=C3)OC(F)(F)F)C(=O)N1CC4=NC=CC=N4
|
|||
| InChI |
1S/C21H16F3N3O3/c22-21(23,24)30-16-5-2-14(3-6-16)15-4-7-18-17(12-15)20(28)27(10-11-29-18)13-19-25-8-1-9-26-19/h1-9,12H,10-11,13H2
|
|||
| InChIKey |
YNUAEEJQYHYLMS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1443211-72-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Late inward sodium current (LISC) | Target Info | Modulator | [4] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8413). | |||
| REF 2 | ClinicalTrials.gov (NCT02300558) Effect of GS-6615 on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT-3 Syndrome. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of Gilead. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.